Vyvanse (lisdexamfetamine dimesylate) is a small molecule pharmaceutical. Lisdexamfetamine dimesylate was first approved as Vyvanse on 2007-02-23. It is used to treat attention deficit disorder with hyperactivity and binge drinking in the USA. Vyvanse's patent is valid until 2023-02-24 (FDA).
|Common Name||Lisdexamfetamine dimesylate|
|Indication||attention deficit disorder with hyperactivity, binge drinking|
|Drug Class||Amfetamine derivatives|